Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab biosimilar - Livzon Mabpharm

Next Previous
Drug Profile

Tocilizumab biosimilar - Livzon Mabpharm

Alternative Names: BOW-070; LZM 008; Recombinant humanized anti-human IL-6R monoclonal antibody solution for injection - Livzon Mabpharm

Latest Information Update: 31 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Developer EPIRUS Biopharmaceuticals; Livzon Mabpharm
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Rheumatoid arthritis
  • Discontinued Giant lymph node hyperplasia

Most Recent Events

  • 18 Jan 2023 Registered for Rheumatoid arthritis (Treatment-experienced, In adults) in China (IV)
  • 29 Sep 2022 Discontinued - Preclinical for Giant lymph node hyperplasia in China (IV)
  • 29 Sep 2022 Preregistration for Rheumatoid arthritis (In adults, Treatment-experienced) in China (IV) before June 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top